Skip to content
Atlas Research Compounds

Cortagen vs. Semax

A structured research comparison between Cortagen and Semax across compound identity, research category, evidence maturity, and interpretation boundaries.

Short peptide bioregulator

Cortagen

Proposed as a tissue-associated short peptide bioregulator; target-level evidence remains limited.

Evidence score1/5

Preclinical foundation

The score summarizes evidence maturity, not safety, effectiveness, or suitability for any use.

Open full profile →

ACTH-fragment-derived neuropeptide

Semax

Investigated across neurotrophic, transcriptional, and stress-response signaling; no single mechanism explains the full literature.

Evidence score2/5

Early human evidence

The score summarizes evidence maturity, not safety, effectiveness, or suitability for any use.

Open full profile →

Side-by-side research context

DimensionCortagenSemax
Catalog identityCortagen is mapped to short peptide bioregulator research.Semax is mapped to ACTH-fragment-derived neuropeptide research.
Research categoryCortagen is primarily organized around neural bioregulator models.Semax is primarily organized around neuroprotection and cognition research.
Interpretive boundaryUse the Cortagen profile and verified study pages before inferring mechanism or outcomes.Use the Semax profile and verified study pages before inferring mechanism or outcomes.

Combined literature starting points

Comparison pages organize differences; they do not establish superiority, equivalence, or individual suitability.

  1. 01

    Short peptide bioregulator literature index

    PubMed, U.S. National Library of Medicine · Database

    Open source
  2. 02

    Atlas internal research database

    Internal Research Database · 2026 · Database

    Open source
  3. 03

    Semax literature index

    PubMed, U.S. National Library of Medicine · Database

    Open source